Q-omics provides the consensus-scored CTAGE11P profile across patient tissues and cancer cell-line models. CTAGE11P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CTAGE11P is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CTAGE11P RNA expression shows 13,462 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where CTAGE11P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAGE11P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAGE11P survival associations across molecular data types. CTAGE11P RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAGE11P RNA expression–survival associations across cancer types. High CTAGE11P expression shows unfavorable associations in ACC, MESO, STAD, UCEC, PAAD and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CTAGE11P RNA expression.
This table summarizes CTAGE11P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CTAGE11P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAGE11P shows lower tumor expression in THCA and higher tumor expression in UCEC, LIHC, BRCA, LUAD and BLCA. The THCA box plot shows higher CTAGE11P RNA expression in normal versus tumor tissue (log2 FC = −0.084, t-test p = .005).
This table shows molecular features associated with CTAGE11P in patient tissues and cancer cell lines. In patient samples, CTAGE11P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAGE11P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and NCI60_ALL.
